Alx Oncology Holdings Inc financial data

Symbol
ALXO on Nasdaq
Industry
Pharmaceutical Preparations
Location
323 Allerton Avenue, South San Francisco, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 7, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 490 % -45.3%
Debt-to-equity 31.6 % +69.3%
Return On Equity -93 % -41%
Return On Assets -70.7 % -27.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 52.7M shares +5.87%
Common Stock, Shares, Outstanding 52.7M shares +28.2%
Entity Public Float 161M USD -6.49%
Common Stock, Value, Issued 53K USD +29.3%
Weighted Average Number of Shares Outstanding, Basic 52.7M shares +28.1%
Weighted Average Number of Shares Outstanding, Diluted 52.7M shares +28.1%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 135M USD +7.52%
General and Administrative Expense 25.3M USD -13.7%
Operating Income (Loss) -160M USD -3.5%
Net Income (Loss) Attributable to Parent -151M USD -3.5%
Earnings Per Share, Basic -2.97 USD/shares +16.8%
Earnings Per Share, Diluted -2.97 USD/shares +16.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 16.1M USD -17.8%
Other Assets, Current 1.23M USD
Assets, Current 156M USD -21.7%
Property, Plant and Equipment, Net 3.11M USD -14%
Operating Lease, Right-of-Use Asset 4.23M USD -16.1%
Other Assets, Noncurrent 12.7M USD +15.4%
Assets 186M USD -15.6%
Accounts Payable, Current 7.89M USD -39.3%
Employee-related Liabilities, Current 4.64M USD +15.9%
Liabilities, Current 32.3M USD -7.97%
Operating Lease, Liability, Noncurrent 3.71M USD -19.9%
Other Liabilities, Noncurrent 6.73M USD +1.43%
Liabilities 48.9M USD -4.77%
Accumulated Other Comprehensive Income (Loss), Net of Tax 563K USD
Retained Earnings (Accumulated Deficit) -592M USD -34.3%
Stockholders' Equity Attributable to Parent 137M USD -18.9%
Liabilities and Equity 186M USD -15.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -37.9M USD -36.3%
Net Cash Provided by (Used in) Financing Activities 3.09M USD
Net Cash Provided by (Used in) Investing Activities 26.5M USD -37.4%
Common Stock, Shares Authorized 1B shares 0%
Common Stock, Shares, Issued 52.7M shares +28.2%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 16.2M USD -17.7%
Deferred Tax Assets, Valuation Allowance 96.3M USD +203%
Operating Lease, Liability 4.63M USD -15.1%
Payments to Acquire Property, Plant, and Equipment 148K USD -78.6%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -150M USD -3.87%
Lessee, Operating Lease, Liability, to be Paid 5.79M USD -17.8%
Property, Plant and Equipment, Gross 5M USD +7.62%
Operating Lease, Liability, Current 923K USD +12.2%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.16M USD -27.3%
Deferred Tax Assets, Operating Loss Carryforwards 26.5M USD +62.5%
Unrecognized Tax Benefits 3.12M USD +87.8%
Operating Lease, Payments 313K USD +0.97%
Depreciation, Depletion and Amortization 214K USD +0.47%
Deferred Tax Assets, Net of Valuation Allowance 97.9M USD +192%
Share-based Payment Arrangement, Expense 28M USD +8.16%
Interest Expense 1.72M USD +24.3%